Browse Category

NASDAQ:RZLT News 11 December 2025 - 24 December 2025

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (Nasdaq: RZLT) is still in the spotlight on December 24, 2025, after a brutal mid-December selloff tied to its pivotal clinical trial news—and a wave of follow-on analyst downgrades, price-target resets, and investor-law-firm investigations. As of the latest available pricing around $2.42 per share, the stock is off its post-trial lows but remains dramatically below pre-readout levels, leaving…
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87%…
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

U.S. stocks closed mixed on Thursday, December 11, 2025, as a historic surge in the Dow clashed with a sharp tech sell‑off led by Oracle and a wave of brutal collapses in thinly traded micro‑caps. By the closing bell (4 p.m. ET), the Dow Jones Industrial Average was up roughly 1.3–1.4% and at a record high, while the S&P 500 edged about 0.1–0.2% higher. The Nasdaq Composite,…
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11, 2025 is one of the ugliest “losers lists” investors have seen this year. Below is a news‑driven breakdown of what’s…

Stock Market Today

  • Chubb (CB) Stock Valuation Review: Is the Market Missing Value?
    February 3, 2026, 11:54 AM EST. Chubb (NYSE: CB) closed recently at $311.25, showing an 8.96% gain over 90 days and a 102.33% total return over five years, highlighting strong momentum. Despite this, the stock trades at a 52% intrinsic value discount with a suggested fair value of $320.96. Investors face a nuanced picture: international growth, rising insurance penetration, and digital sales innovation point to revenue and margin gains. Yet, risks like intensified competition in large property accounts and catastrophe-related costs could pressure profitability. Valued at a price-to-earnings (P/E) ratio of 12.7x, above peers but below industry average and its own fair multiple, Chubb's share price reflects a complex balance of growth prospects and market concerns.
Go toTop